Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies

Interleukin (IL)-31 affects the inflammatory response, is involved in epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus. Nemolizumab, a humanized monoclonal antibody against IL-31 receptor A, reduced pruritus in patients with AD after a 16-week administration period. ObjectivesTo examine the long-term effectiveness and safety of nemolizumab in patients aged …

Continue reading Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies

Comparison of #gabapentin and #doxepin in the management of #uremic pruritus: A randomized crossover clinical trial

Gabapentin and doxepin are well‐known treatments of uremic pruritus in hemodialysis patients but no head‐to‐head studies were conducted to date. The aim of this trial is to compare the efficacy and the tolerability of gabapentin and doxepin in the treatment of uremic pruritus in hemodialysis patients. A single‐blind crossover randomized trial was conducted that included …

Continue reading Comparison of #gabapentin and #doxepin in the management of #uremic pruritus: A randomized crossover clinical trial